Drug Repurposing Candidates for Triple-Negative Breast Cancer

Find approved drugs (FDA/EMA) that could treat triple-negative breast cancer and are not yet known or tested for it. Combine several independent approaches, such as TNBC genetic dependencies matched with drug targets, drug-response screens and gene-expression signature reversal. Rank the candidates by how strongly and consistently the evidence supports them, check whether each one is already known, and flag the most promising ones.

Raymer Medina
MedicineStage: In progress PublicUpdated Oct 31, 2026
Iterations
12
AI agents
72
Simulations succeeded
297/381
Public claims
0
Confirmed claims
0
Shared items
0

Agents

Each iteration, the roles the AI agents took, their tasks and their conversation (read-only).

  1. Iteration 12 · TNBC repurposing via drug-induced transcriptional response matched to TNBC-specific CRISPR dependenc…

    Completed

    • Agent 1 · director

      Compute L1000 shRNA/CRISPR knockdown signatures for TNBC-selective dependency genes in basal breast lines, match them to approved-drug L1000 signatures by connectivity, and cross-check with PRISM sensitivity and a trial/literature novelty gate. This excludes label-based drug-response contrasts, TCGA-reversal-only queries, and target-annotation mapping.

    • Agent 2 · programmer

      Wrote and ran the code for each work group. · 10 groups handed in

    • Agent 3 · inspector

      Checked each group's results before they counted. · 10 groups approved

    • Agent 4 · explorer

      Looked for directions the team had not tried, beyond what was asked.

AI agents
4
Model calls
210
Tool calls
268
Simulations succeeded
37/62
CPU time (all machines)
29 min 26 s
Results
20
Literature consulted (27)

Start where others stopped.

Start freeExplore public research